Rituximab Therapy for the Patients With HTLV-1-associated Myelopathy

Trial Information
Who is this study for? Patients with Multiple System Atrophy
What treatments are being studied? Rituximab
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2

Neuroprotective or anti-inflammatory strategies are invaluable in HTLV-1-associated myelopathy due to its rapid progression. We evaluated the efficacy of rituximab in patients with HTLV-1-associated myelopathy.

Am I eligible for this trial?
Participation Requirements
Minimum Age:
Maximum Age:
Healthy Volunteers:

• Age 18-80 years

• Patients HTLV-1-associated myelopathy (tropical spastic paraparesis)

Where is this trial taking place?
Other Locations
Department of Neurology ,First Affiliated Hospital Fujian Medical University
When is this trial taking place?
Start Date: August 15, 2019
Estimated Completion Date: July 2024
How many participants will be in this trial?
Target number of participants: 100
What treatment is being studied in this trial?
Experimental: Rituximab group
Rituximab will be administered as 100 mg IV, once per week for 3 consecutive weeks. Continued dosage was dependent on the percentage of circulating CD19 B-cell counts from patients . Whenever it reached 1% of total lymphocyte population, rituximab 100 mg was reinfused
No Intervention: Control group
Patients will receive usual care and drug use.
Who are the authors of this trial?
Wan-Jian Chen
What other conditions are being studied in this trial?

This content was sourced from clinicaltrials.gov